Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds with high affinity to somatostatin receptor subtypes (mainly sst2 and sst5) on pituitary and neuroendocrine cells. This binding inhibits adenylate cyclase activity, suppresses secretion of growth hormone, insulin‑like growth factor‑1, and various peptide hormones, thereby controlling tumor growth and hormone‑driven symptoms.

The dosing regimen for Myrelez is individualized by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. The prescriber determines the injection volume, frequency (typically every 4 weeks), and any necessary adjustments, following the product’s labeling and clinical guidelines.

Safety data for lanreotide acetate in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider before initiating therapy.

To place an order, submit an enquiry on the Myrelez product page at gnhindia.com, specifying the required quantity and providing institutional credentials such as a pharmacy or hospital license. GNH India’s commercial team will verify the documentation, then respond with pricing, availability, shipping details (including cold‑chain logistics if required), and any necessary import paperwork.

Myrelez (lanreotide acetate) and other long‑acting somatostatin analogs such as octreotide LAR share a similar mechanism of receptor binding and are both used for acromegaly and neuroendocrine tumors. Differences lie in dosing intervals (lanreotide can be administered every 4 weeks, octreotide LAR often every 4 weeks as well), formulation (pre‑filled syringe vs. vial), and individual patient tolerability, which clinicians consider when selecting therapy.

Myrelez should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial or pre‑filled syringe. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 days, then return to refrigeration.

Myrelez is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection is performed by a qualified healthcare professional or a trained patient using the supplied pre‑filled syringe or vial with appropriate needle. Injections are usually scheduled every four weeks, but the exact interval is determined by the prescribing clinician based on therapeutic response.

The most serious adverse reactions reported with lanreotide acetate include gallbladder disease (such as cholelithiasis or cholecystitis), pancreatitis, severe hyperglycaemia or new‑onset diabetes, and hypersensitivity reactions that can be life‑threatening (anaphylaxis). Patients should be monitored regularly for abdominal pain, changes in blood glucose, and any signs of allergic response, and treatment should be discontinued if severe events occur.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any of the excipients in the formulation. Caution is advised for individuals with severe uncontrolled diabetes, active gallbladder disease, or those who are pregnant or breastfeeding unless the potential benefit outweighs the risk. Decision to treat should be made by a qualified physician after evaluating these factors.